IV Relenza saves U.K. woman from H1N1 flu

Mainlining GlaxoSmithKline's Relenza could end up as the swine-flu treatment of last resort. British doctors saved the life of a woman with severe H1N1 flu, using an unapproved IV form of the Glaxo antiviral. Report

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.